Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx Announces Proposed Public Offering of Common Stock

GlobeNewswire February 25, 2019

Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Benzinga.com  February 25, 2019

Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

GlobeNewswire February 21, 2019

Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Update

GlobeNewswire February 19, 2019

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update

GlobeNewswire February 12, 2019

Ultragenyx Appoints Shehnaaz Suliman, M.D., to Board of Directors

GlobeNewswire February 4, 2019

Ultragenyx Announces Positive Topline Data from Ongoing Long-Term Extension Study of UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders

GlobeNewswire January 22, 2019

New Research Coverage Highlights Arthur J. Gallagher, Ultragenyx Pharmaceutical, Empire State Realty Trust, ConocoPhillips, Kilroy Realty, and NETGEAR — Consolidated Revenues, Company Growth, and Expectations for 2019

GlobeNewswire January 11, 2019

Ultragenyx Announces Positive Topline Results from First Cohort of Phase 1/2 Clinical Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

GlobeNewswire January 4, 2019

Ultragenyx to Present at J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2019

Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™ (burosumab injection) for the Treatment of X–linked Hypophosphatemia (XLH) in Adults and Children

GlobeNewswire December 6, 2018

Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019

GlobeNewswire November 14, 2018

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire November 9, 2018

Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire November 9, 2018

Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update

GlobeNewswire November 5, 2018

Ultragenyx to Host Conference Call for Third Quarter 2018 Financial Results and Corporate Update

GlobeNewswire October 30, 2018

Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in Patients with Glut1 DS with Disabling Movement Disorders

GlobeNewswire October 26, 2018

Ultragenyx Announces Exclusive License to REGENXBIO AAV Vectors to Develop Gene Therapy for CDD (CDKL5 Deficiency Disorder)

GlobeNewswire October 22, 2018

Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Brazil for the Treatment of Mucopolysaccharidosis VII

GlobeNewswire October 18, 2018

Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding, Summit Midstream Partners, LP, and Seattle Genetics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire October 3, 2018